Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1995 1
1996 1
1998 2
2000 2
2001 1
2003 1
2005 2
2006 4
2007 2
2008 7
2009 2
2010 4
2011 6
2012 7
2013 6
2014 7
2015 10
2016 8
2017 7
2018 2
2019 5
2020 1
2021 4
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Antisense technology: an overview and prospectus.
Crooke ST, Baker BF, Crooke RM, Liang XH. Crooke ST, et al. Among authors: crooke rm. Nat Rev Drug Discov. 2021 Jun;20(6):427-453. doi: 10.1038/s41573-021-00162-z. Epub 2021 Mar 24. Nat Rev Drug Discov. 2021. PMID: 33762737 Review.
Antisense technology: A review.
Crooke ST, Liang XH, Baker BF, Crooke RM. Crooke ST, et al. Among authors: crooke rm. J Biol Chem. 2021 Jan-Jun;296:100416. doi: 10.1016/j.jbc.2021.100416. Epub 2021 Feb 16. J Biol Chem. 2021. PMID: 33600796 Free PMC article. Review.
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
Semova I, Levenson AE, Krawczyk J, Bullock K, Gearing ME, Ling AV, Williams KA, Miao J, Adamson SS, Shin DJ, Chahar S, Graham MJ, Crooke RM, Hagey LR, Vicent D, de Ferranti SD, Kidambi S, Clish CB, Biddinger SB. Semova I, et al. Among authors: crooke rm. Circulation. 2022 Mar 29;145(13):969-982. doi: 10.1161/CIRCULATIONAHA.120.045373. Epub 2022 Feb 23. Circulation. 2022. PMID: 35193378 Free PMC article. Clinical Trial.
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Graham MJ, et al. Among authors: crooke rm. N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24. N Engl J Med. 2017. PMID: 28538111 Free article. Clinical Trial.
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W, De Hoyos CL, Migawa MT, Vickers TA, Sun H, Low A, Bell TA 3rd, Rahdar M, Mukhopadhyay S, Hart CE, Bell M, Riney S, Murray SF, Greenlee S, Crooke RM, Liang XH, Seth PP, Crooke ST. Shen W, et al. Among authors: crooke rm. Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29. Nat Biotechnol. 2019. PMID: 31036929
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Viney NJ, et al. Among authors: crooke rm. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. Lancet. 2016. PMID: 27665230 Clinical Trial.
89 results